A personal interest often is key to finding
financial support for controversial stem cell research
(wz) Times are tough for biotechnology companies hoping to raise private investment capital.
Venture capital firms generally wait longer – until a product is more fully developed – before they are willing to risk their money in biotech.
That makes it almost impossible for companies working on human embryonic stem cell research to find financing because…
so much is unknown about how those few cells morph into the more than 200 cell types in the body.
Using human embryonic stem cells to develop cures and treatments for Parkinson’s disease, heart disease, cancers and other ailments is still decades away, say those in the field. more…
From: »Greater Paramus News«